Get the Stockscreener App
1.94
3.00%
-0.0599
Pre-market:
1.91
-0.03
-1.55%
22nd Century Group, Inc. stock is traded at $1.94, with a volume of 48,958.
It is down -3.00% in the last 24 hours and down -37.22% over the past month.
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM, a line of research cigarettes for use in independent clinical studies. The company's products under development include BRAND A, a very low nicotine cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; and BRAND B, a low-tar-to-nicotine ratio cigarette. In addition, it engages in contract manufacturing business for third-party branded tobacco products. The company has scientific collaborations with the University of Virginia and Anandia Laboratories, Inc. to develop proprietary hemp strains with less than 0.3% dry weight content of delta-9-tetrahydrocannabinol. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.
See More
Previous Close:
$1.9999
Open:
$1.91
24h Volume:
48,958
Relative Volume:
0.06
Market Cap:
$3.33M
Revenue:
$29.78M
Net Income/Loss:
$-39.94M
P/E Ratio:
-0.0313
EPS:
-61.9139
Net Cash Flow:
$-16.12M
1W Performance:
-6.28%
1M Performance:
-37.22%
6M Performance:
-95.80%
1Y Performance:
-99.33%
1-Day Range:
$1.82
$2.03
1-Week Range:
$1.79
$2.1489
52-Week Range:
$1.75
$581.85
22nd Century Group, Inc. Stock (XXII) Company Profile
Name
22nd Century Group, Inc.
Sector
Industry
Phone
716-270-1523
Address
8560 Main Street, Williamsville, NY
Compare XXII with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XXII
22nd Century Group, Inc.
|
1.94 | 3.33M | 29.78M | -39.94M | -16.12M | -61.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
22nd Century Group, Inc. Stock (XXII) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-22 | Initiated | Alliance Global Partners | Buy |
| Jun-15-22 | Initiated | Craig Hallum | Buy |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Jul-23-21 | Initiated | Cowen | Outperform |
| Oct-16-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-11-16 | Reiterated | Chardan Capital Markets | Buy |
View All
22nd Century Group, Inc. Stock (XXII) Latest News
22nd Century Group to Announce Fourth Quarter and Full Year 2024 Results on March 20, 2025 - The Manila Times
12 Cannabis Stocks to Buy Now in 2025 - MarketBeat
22nd Century Announces First Partner VLN Agreement, New VLN Availability with Smoker Friendly - GlobeNewswire
22nd Century Group expands VLN products with Smoker Friendly - Investing.com India
XXII stock plunges to 52-week low, touches $3.03 amid market rout - MSN
Weiss Ratings Reiterates “Sell (E)” Rating for 22nd Century Group (NASDAQ:XXII) - Defense World
XXII stock plunges to 52-week low of $1.72 amid market challenges - Investing.com Australia
22nd Century regains compliance with the Nasdaq - MSN
XXII stock plunges to 52-week low of $2.98 amid market challenges - Investing.com Nigeria
XXII stock plunges to 52-week low of $2.98 amid market challenges By Investing.com - Investing.com South Africa
22nd Century Group (NASDAQ:XXII) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
Emerging Growth Research Releases New Initiation Report on the 22nd Century Group (XXII) - Newsfile
22nd Century : FDA Lead Scientist Discusses 22nd Century’s SPECTRUM® Research Cigarettes in Public Webcast - Marketscreener.com
22nd Century Group, Inc. (NASDAQ:XXII) Short Interest Down 63.8% in January - Defense World
XXII stock plunges to 52-week low, touches $3.03 amid market rout By Investing.com - Investing.com South Africa
22nd Century to Present at the Emerging Growth Conference on February 19, 2025 - Marketscreener.com
Exclusive: 22nd Century Group Unveils Strategic Vision at Emerging Growth ConferenceCEO Takes Center Stage - StockTitan
Weiss Ratings Reiterates Sell (E) Rating for 22nd Century Group (NASDAQ:XXII) - Defense World
22nd Century files to sell 104,124 shares of common stock for holders - MSN
22nd Century Sells Cannabis Operations - Tobacco Reporter
Investors Buy 22nd Shares ‘Above Market’ - Tobacco Reporter
22nd Century Launches Public Offering - Tobacco Reporter
22nd Century Submits CBD Drug Master File - Tobacco Reporter
22nd Century Eliminates $2.3 million of Debt - Tobacco Reporter
22nd Century Reports Quarterly Results - Tobacco Reporter
22nd Century Group (NASDAQ: XXII) and Smoker Friendly Forge New Agreement – Market - HPBL
22nd Century Group (NASDAQ:XXII) Regains Compliance with Nasdaq Listing Rule 5550(a)(2) - Defense World
22nd Century Regains Full Compliance with Nasdaq Continued Listing Standards - The Manila Times
22nd Century Group Regains Nasdaq Compliance, Secures Exchange Listing - StockTitan
22nd Century Group Announces Strategic Agreement with Smoker Friendly – Market - HPBL
FDA Publishes Proposed New Tobacco Product Standard for Nicotine Yield, Citing VLN from 22nd Century as the Only Combustible Cigarette That Complies with the New Standard - The Manila Times
22nd Century Group's VLN Cigarettes Already Meet FDA's Proposed Nicotine Reduction Standard - StockTitan
22nd Century Group Resets Conversion Price in Senior Secured Credit Facility - Defense World
Washington Post Story Featuring 22nd Century VLN Products Highlights Proposed FDA Reduced Nicotine Content Policy Could Initially Benefit An Estimated 13 Million Smokers - The Manila Times
22nd Century's VLN Cigarettes Take Spotlight as FDA's Nicotine Reduction Plan Advances - StockTitan
22nd Century Group Stock Rises On Proposed FDA Mandate On Nicotine Content: Retail's Extremely Bullish - MSN
22nd Century Group, Inc. Stock (XXII) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):